3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Signs and Symptoms
1
Psoriasis
1
Nutrition Disorders
1
Insulin Resistance
1
Inflammatory Bowel Diseases
1
Glioma
1
Glioblastoma
1
Gastroparesis
1
Feeding and Eating Disorders
1
Esophageal Neoplasms
1
Dumping Syndrome
1
Diarrhea
1
Breast Neoplasms
1
Brain Neoplasms
1
Arthritis, Rheumatoid
1
Interventions
Temozolomide
203
Radiotherapy
118
Bevacizumab
93
Radiation
40
Magnetic Resonance Spectroscopy
28
Irinotecan
27
Carmustine
25
Surgical Procedures, Operative
24
Lomustine
21
Erlotinib Hydrochloride
19
Chemotherapy, Adjuvant
18
Carboplatin
17
temsirolimus
13
Drug Therapy
13
O(6)-benzylguanine
12
Nivolumab
12
sargramostim
11
Sirolimus
11
Radiotherapy, Intensity-Modulated
11
Radiotherapy, Conformal
11
Sorafenib
10
Radiosurgery
10
Imatinib Mesylate
10
Everolimus
10
pembrolizumab
9
motexafin gadolinium
9
Vorinostat
9
Thalidomide
8
IL13-PE38
8
Gefitinib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Glioblastoma
×
Sulfasalazine
×
Clear all
NCT04205357
2023-03-03
SAS-GKRS
Haukeland University Hospital
Phase 1
Completed
24 enrolled